Acenaphthylenol | 89556-83-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 吖萘类
• 英文名称: Acenaphthylenol
• 英文别名: acenaphthylen-1-ol
• CAS: 89556-83-2
• 化学式: C₁₂H₈O
• 分子量: 168.19
• InChiKey: YNVMLVRRRZVVKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR
  申请人：Miyata Toshio

  公开号：US20090124620A1

  公开（公告）日：2009-05-14

  The present invention relates to an inhibitor of plasminogen activator inhibitor-1. The present invention further relates to a pharmaceutical composition that has an inhibitory action on PAI-1 activity and is useful in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity. Furthermore, the present invention relates to a novel compound having PAI-1 inhibitory activity represented by the following general formula (I), and a salt thereof. Each symbol is defined as those in the specification.

  本发明涉及一种抑制纤溶酶原激活物抑制剂-1的抑制剂。本发明进一步涉及一种对PAI-1活性具有抑制作用的药物组合物，可用于预防和治疗与PAI-1活性相关的各种疾病的发生。此外，本发明涉及一种具有PAI-1抑制活性的新化合物，其由以下一般式（I）表示，并且其盐。每个符号的定义如规范中所述。
• Amide derivatives
  申请人：Muto Susumu

  公开号：US20050215645A1

  公开（公告）日：2005-09-29

  A medicament for enhancing an effect of a cancer therapy based on a mode of action of DNA injury, which comprises as an active ingredient a compound represented by the following general formula (I) or a salt thereof: wherein one of R 1 and R 2 represents hydrogen atom and the other represents the formula —X-A wherein A represents hydrogen atom or an acyl group, X represents oxgen atom or NH; one of R 3 and R 4 represents hydrogen atom and the other represents the following formula: wherein Y represents a sulfonyl group or a carbonyl group, R 5 represents a cyclic group, Z represents a single bond or a C 1 to C 4 alkylene group, R 6 represents hydrogen atom or a C 1 to C 6 alkyl group.

  一种用于增强基于DNA损伤作用的癌症治疗效果的药物，其活性成分为以下一般式(I)或其盐表示的化合物：其中R1和R2中的一个代表氢原子，另一个代表式—X-A，其中A代表氢原子或酰基，X代表氧原子或NH；R3和R4中的一个代表氢原子，另一个代表以下式：其中Y代表磺酰基或羰基，R5代表环状基团，Z代表单键或C1到C4烷基烷基，R6代表氢原子或C1到C6烷基基团。
• NOVEL ANTICANCER AGENT
  申请人：KYOTO PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：US20170121299A1

  公开（公告）日：2017-05-04

  The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.

  本发明的问题是提供一种有用的萘呋喃化合物的前药化合物。本发明涉及一种由公式（IA）表示的化合物：[其中每个符号如描述所述]或其药学上可接受的盐。
• INFLAMMATORY CYTOKINE RELEASE INHIBITOR
  申请人：MUTO Susumu

  公开号：US20090192122A2

  公开（公告）日：2009-07-30

  A medicament having inhibitory activity against NF-κB activation, which comprises a compound represented by the following general formula (I) or a pharmacologically acceptable salt as an active ingredient: wherein X represents a connecting group, A represents hydrogen atom or acetyl group, E represents an aryl group or a heteroaryl group, and ring X represents an arene or a heteroarene.

  一种具有抑制NF-κB激活活性的药物，其包括以下通式(I)所表示的化合物或其药理学上可接受的盐作为活性成分：其中X代表连接基，A代表氢原子或乙酰基，E代表芳基或杂芳基，环X代表芳烃或杂芳烃。
• Nf-kb activation inhibitors
  申请人：Muto Susumu

  公开号：US20060089395A1

  公开（公告）日：2006-04-27

  A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is circle around (1)} a fused polycyclic heteroaryl group wherein the ring which binds directly to —CONH— group in the formula (I) is a benzene ring, circle around (2)} unsubstituted thiazol-2-yl group, or circle around (3)} unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above.

  一种药物具有抑制NF-κB活化作用，其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分，其中A代表氢原子或乙酰基，E代表2,5-二取代或3,5-二取代苯基或单环或融合的多环杂环芳基，其可以被取代，但在所述杂环芳基是圆圈(1)}在公式(I)中直接结合—CONH—基团的环为苯环的融合多环杂环芳基，圆圈(2)}未取代的噻唑-2-基团，或者圆圈(3)}未取代的苯并噻唑-2-基团时，不包括该化合物，环Z代表一个芳香烃，除了由公式—O-A所表示的基团外，它也可以有一个或多个取代基，其中A具有与上述定义相同的含义，公式—CONH-E所表示的基团E具有与上述定义相同的含义。